Marqeta Inc vs Nuwellis Inc — how do they compare? Marqeta Inc trades at $17.22 (market cap $1.85B), while Nuwellis Inc trades at $2.84 (market cap $1.09M). The key difference: Marqeta Inc is far larger — about 1697.2× Nuwellis Inc's market cap, and Marqeta Inc is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.
| MQ | NUWE | |
|---|---|---|
Market Cap | $1.85B | $1.09M |
Sector | Technology | Technology |
52-Week High | $27.32 | $527.46 |
52-Week Low | $15.04 | $2.80 |
Enterprise Value | $1.15B | -$722.58K |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
NUWE trades at $3.00, up 5.26% today, following a 35:1 reverse stock split effective June 26, 2026. The company shows a low P/E of 0.06 and P/S of 0.01, but fundamentals are weak with a -217.22% net income margin and negative ROE. Recent news highlights patent awards and pediatric market expansion, yet cash flow remains negative. Analyst coverage is limited with a split buy/hold consensus.
Outlook is speculative; growth depends on successful commercialization of Aquadex therapy and cost management. Key risks include persistent losses, high cash burn, and competitive pressures. Investors should weigh low valuation against execution risks in the medical technology sector.
Trailing returns across standard periods
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →